Summarized by Masters of Longevity from FierceBiotech - All.
A news article about a late-stage lung cancer drug trial and what the results could mean for treatment choices and rivals.
Key Takeaways
- In a phase 3 trial, risvutatug rezetecan produced a median overall survival of 18.5 months in patients with lung cancer.
- The antibody-drug conjugate demonstrated efficacy strong enough to position it as a competitive alternative to existing therapies from Amgen and Merck.
- Improved survival with risvutatug rezetecan suggests potential changes to treatment choices and competitive dynamics in lung cancer care.
